 |
|
 |
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PEDIATRICS Vol. 100 No. 1 July 1997, pp. 31-38
Received Apr 22, 1996; accepted Sep 11, 1996.
,
,,,, and
From the * Columbia Wesley Medical Center and University of
Kansas School of Medicine-Wichita, Wichita, Kansas; University of
Virginia, Richmond, Virginia; § Children's Mercy Hospital and
University of Missouri, Kansas City, Missouri; ONY, Inc, Amherst,
New York; ¶ Rutgers University, Piscataway, New Jersey; # University of
Texas Medical Branch at Galveston, Galveston, Texas; ** Newark Beth
Israel Medical Center, Newark, New Jersey; Mount Sinai New York,
New York, New York; §§ University of Alabama at Birmingham,
Birmingham, Alabama; || Louisiana State University in Shreveport,
Shreveport, Louisiana; ¶¶ The University of Oklahoma, Oklahoma City,
Oklahoma; ## University of Kansas Medical Center, Kansas City, Kansas;
*** University of Nebraska Medical Center, Omaha, Nebraska;
Medical College of Virginia, Richmond, Virginia; and
§§§ Research Medical Center, Kansas City, Missouri.
Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract; ONY, Inc, Amherst, NY, IND #27169) versus Survanta (Beractant, Ross Laboratories, Columbus, OH) in reducing the acute severity of respiratory distress syndrome (RDS) when given at birth and to infants with established RDS.
Design. A prospective, randomized, double-blind, multicenter clinical trial.
Setting. Thirteen neonatal intensive care units participated in the treatment arm: seven of these concurrently participated in the prevention arm.
Patients. The treatment arm enrolled infants of 
2000 g
birth weight with established RDS, and the prevention arm enrolled infants of 29 weeks' gestation with birth weights <1250 g.
Intervention. Infants were randomly assigned to receive Infasurf (n = 303, treatment arm; n = 180, prevention arm) or Survanta (n = 305, treatment arm; n = 194, prevention arm) in accordance with the Survanta package insert instructions.
Outcome Measures. We projected a 25% reduction between groups in the need for a third dose of surfactant for infants with established RDS, and a 25% reduction in the need for a second dose of surfactant for infants who received prophylactic surfactant. Secondary outcomes included the severity of RDS measured by inspired oxygen concentrations and mean airway pressure, air leaks, complications associated with surfactant administration, and survival to 36 weeks' postmenstrual age without the need for oxygen supplementation.
Results. In the treatment arm, there was no difference between groups in the number of infants requiring more than two doses of surfactant. The interval between doses was significantly longer for Infasurf, suggesting an increased duration of treatment effect. The inspired oxygen concentration and mean airway pressure were lower in the Infasurf infants during the first 48 hours in the treatment arm.
In the prevention arm, there were no differences with respect to the number of surfactant doses. The dosing intervals were longer for Infasurf infants after the second dose. No difference in inspired oxygen or mean airway pressure was noted during the first 72 hours.
There were no significant differences in the incidence of air leaks, complications associated with dosing, complications of prematurity, mortality, or survival without chronic lung disease in the prevention or treatment arm.
Conclusions. Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.
Key words: respiratory distress syndrome, surfactant, Infasurf, Survanta.
This article has been cited by other articles:
 |
|
 |
|
  W. A. Engle and and the Committee on Fetus and Newborn Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate Pediatrics, February 1, 2008; 121(2): 419 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Braun, P. C. Stenger, H. E. Warriner, J. A. Zasadzinski, K. W. Lu, and H. W. Taeusch A Freeze-Fracture Transmission Electron Microscopy and Small Angle X-Ray Diffraction Study of the Effects of Albumin, Serum, and Polymers on Clinical Lung Surfactant Microstructure Biophys. J., July 1, 2007; 93(1): 123 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, J. Gadzinowski, R. D'Agostino, R. Segal, C. Guardia, J. Mazela, G. Liu, and on behalf of the SELECT and STAR Study Investigato One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials Pediatrics, June 1, 2007; 119(6): e1361 - e1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ghodrat Lung surfactants. Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1504 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Agrons, S. E. Courtney, J. T. Stocker, and R. I. Markowitz From the Archives of the AFIP: Lung Disease in Premature Neonates: Radiologic-Pathologic Correlation RadioGraphics, July 1, 2005; 25(4): 1047 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Willson, N. J. Thomas, B. P. Markovitz, L. A. Bauman, J. V. DiCarlo, S. Pon, B. R. Jacobs, L. S. Jefferson, M. R. Conaway, E. A. Egan, et al. Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung Injury: A Randomized Controlled Trial JAMA, January 26, 2005; 293(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Alonso, T. Alig, J. Yoon, F. Bringezu, H. Warriner, and J. A. Zasadzinski More Than a Monolayer: Relating Lung Surfactant Structure and Mechanics to Composition Biophys. J., December 1, 2004; 87(6): 4188 - 4202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kattwinkel, B. T. Bloom, P. Delmore, C. Glick, D. Brown, S. Lopez, L. Willett, E. A. Egan, M. Conaway, and J. Patrie High-Versus Low-Threshold Surfactant Retreatment For Neonatal Respiratory Distress Syndrome Pediatrics, August 1, 2000; 106(2): 282 - 288. [Abstract] [Full Text]
|
|
|
|
|
|
Committee on Fetus and Newborn Surfactant Replacement Therapy for Respiratory Distress Syndrome Pediatrics, March 1, 1999; 103(3): 684 - 685. [Abstract] [Full Text]
|
|
|
|
|
|
H. Verder, P. Albertsen, F. Ebbesen, G. Greisen, B. Robertson, A. Bertelsen, L. Agertoft, B. Djernes, E. Nathan, and J. Reinholdt Nasal Continuous Positive Airway Pressure and Early Surfactant Therapy for Respiratory Distress Syndrome in Newborns of Less Than 30 Weeks' Gestation Pediatrics, February 1, 1999; 103(2): 24e - 24. [Abstract] [Full Text]
|
|
|
|
|
|
P. L. Ramsay, E. O'Brian Smith, S. Hegemier, and S. E. Welty Early Clinical Markers for the Development of Bronchopulmonary Dysplasia: Soluble E-Selectin and ICAM-1 Pediatrics, October 1, 1998; 102(4): 927 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. HAFNER, P.-G. GERMANN, and D. HAUSCHKE Effects of rSP-C Surfactant on Oxygenation and Histology in a Rat-Lung-Lavage Model of Acute Lung Injury Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. CLEMENTS and M. E. AVERY Lung Surfactant and Neonatal Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): S59 - S66. [Full Text] [PDF]
|
|
 |
||
|
||
Home | My Pediatrics | Journal Information | Current Issue | Past Issues | Subscriptions & Services | Contact Us Click here for faster international access © 1997 American Academy of Pediatrics. All rights reserved. |
||
|
||
